Why is Globus Medical stock plunging today?
Globus Medical (GMED) stock fell 12.5% to $71.26, a 52-week low, after Q3 2026 revenue missed estimates at $763.7M, down 0.7% YoY. The company cut full-year revenue guidance to $3.09B. Analysts downgraded the stock, citing weak growth outlook and insider selling. The S&P 500 and Nasdaq rose, but GMED underperformed.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance reduction triggered a 12.5% price drop, outweighing the EPS beat.
Market read
Earnings-driven sell‑off in a mid‑cap medical‑device stock, contrasting with a broadly positive market.
What to watch
Non‑GAAP EPS beat and stable EPS guidance may provide some floor support.
Background
Globus Medical reported Q3 2026 results with a modest EPS beat but a significant revenue miss and lowered full‑year outlook.
Ticker impact
Q3 2026 results missed revenue expectations and guidance was cut, causing a 12.5% mid‑day price plunge.
likely further downside as investors price in the revenue shortfall and reduced guidance
Revenue fell 0.7% YoY, missing consensus by $28M, and full‑year revenue guidance was cut by up to $130M, triggering a sharp sell‑off.
Market effects
Medical device sector underperforms despite broader market gains, highlighting company‑specific weakness.
U.S. equities broadly higher, but GMED drags down the healthcare sub‑index.
Limited; impact confined to U.S. listed medical‑device stocks.
Counterpoint
If the market overreacts to the guidance cut, a short‑term bounce could occur on any positive news.
Key entities
- companyGlobus Medical
Medical device manufacturer (ticker GMED).
- analystBMO Capital
Downgraded GMED to Market Perform.
